Exploring Leap Therapeutics, Inc. (LPTX) Investor Profile: Who’s Buying and Why?

Are you tracking the movements of institutional investors and wondering who is making strategic plays in Leap Therapeutics, Inc. (LPTX)? With a market cap of approximately $67.98 million, understanding the dynamics of who is investing and why becomes crucial. Did you know that institutional ownership accounts for a significant 55.70% of the company's shares? As of the last update, notable holders include entities like Vanguard Group Inc. and BlackRock Fund Advisors, reflecting confidence from major players. Dive in to uncover the latest shifts in LPTX's investor landscape, exploring the motivations behind these investment decisions and what they signal for the future of this biopharmaceutical company.

Leap Therapeutics, Inc. (LPTX) Who Invests in Leap Therapeutics, Inc. and Why?

Understanding the investor profile of Leap Therapeutics, Inc. (LPTX) provides valuable insights into the company's perceived potential and market dynamics. Investors are typically categorized into retail investors, institutional investors, and hedge funds, each bringing different investment strategies and motivations.

Key Investor Types:

The investor base of Leap Therapeutics, Inc. includes a mix of retail and institutional investors.

• Retail Investors: These individual investors often respond to news, clinical trial updates, and general market sentiment. Their investment decisions may be influenced by the potential for quick gains or a belief in the company's long-term vision.
• Institutional Investors: These include mutual funds, pension funds, and investment firms. Institutions often conduct thorough due diligence and invest based on a longer-term outlook. Their presence can lend credibility to Leap Therapeutics, Inc. and influence stock stability.
• Hedge Funds: These funds may take more aggressive positions, seeking short-term gains from trading opportunities around clinical trial results or corporate announcements.

Investment Motivations:

Several factors attract investors to Leap Therapeutics, Inc.:

• Growth Prospects: The biotechnology sector is known for high-growth potential, especially for companies developing novel therapies. Positive clinical trial results can significantly boost investor confidence.
• Market Position: Leap Therapeutics, Inc.’s focus on specific therapeutic areas and its pipeline of drug candidates position it within a competitive but potentially lucrative market.

Investment Strategies:

The strategies employed by investors in Leap Therapeutics, Inc. can vary widely:

• Long-Term Holding: Some investors adopt a long-term approach, banking on the company's ability to bring its drug candidates to market and generate sustained revenue.
• Short-Term Trading: Other investors may engage in short-term trading, capitalizing on volatility around news events and clinical trial data.
• Value Investing: Value investors seek to identify undervalued companies with strong fundamentals and growth potential, viewing Leap Therapeutics, Inc. as an opportunity for long-term appreciation.

To gain more insight into the company's objectives, explore the Mission Statement, Vision, & Core Values of Leap Therapeutics, Inc. (LPTX).

Leap Therapeutics, Inc. (LPTX) Institutional Ownership and Major Shareholders of Leap Therapeutics, Inc. (LPTX)

Institutional ownership in Leap Therapeutics, Inc. (LPTX) provides insights into the confidence and influence that large financial entities have in the company's stock. Examining the top institutional investors, changes in ownership, and the overall impact they have can help investors understand market sentiment and potential stock performance.

As of March 31, 2024, the largest institutional investors in Leap Therapeutics, Inc. (LPTX) included:

• FMR LLC: Holding 2,614,913 shares
• RA Capital Management, L.P.: Holding 2,348,027 shares
• Vanguard Group, Inc. (The): Holding 2,151,651 shares
• Blackrock Inc.: Holding 1,373,026 shares
• State Street Corporation: Holding 633,930 shares

These institutional investors collectively hold a significant percentage of Leap Therapeutics, Inc. (LPTX)'s outstanding shares, reflecting their substantial interest in the company's prospects.

Recent changes in ownership among institutional investors can signal shifts in sentiment and future stock performance. For example:

• FMR LLC increased its holdings by 453,863 shares (21.04% change) in the first quarter of 2024.
• RA Capital Management, L.P. increased its holdings by 22,419 shares (0.96% change) in the first quarter of 2024.
• Vanguard Group, Inc. (The) increased its holdings by 150,751 shares (7.53% change) in the first quarter of 2024.
• Blackrock Inc. increased its holdings by 153,040 shares (12.54% change) in the first quarter of 2024.
• State Street Corporation increased its holdings by 40,340 shares (6.80% change) in the first quarter of 2024.

These increases suggest a growing confidence among major institutional players in Leap Therapeutics, Inc. (LPTX).

Institutional investors play a crucial role in shaping a company's stock price and strategy. Their substantial holdings can lead to increased trading volume and price stability. Moreover, their investment decisions often influence market perception and investor confidence. The presence of reputable institutional investors can enhance Leap Therapeutics, Inc. (LPTX)'s credibility and attract further investment.

Here is a detailed breakdown of institutional ownership changes in Q1 2024:

Understanding these ownership dynamics can provide valuable insights for current and potential investors in Leap Therapeutics, Inc. (LPTX).

To gain more insights into the values and direction of the company, check out: Mission Statement, Vision, & Core Values of Leap Therapeutics, Inc. (LPTX).

Leap Therapeutics, Inc. (LPTX) Key Investors and Their Impact on Leap Therapeutics, Inc. (LPTX)

Understanding the investor profile of Leap Therapeutics, Inc. (LPTX) is crucial for grasping the dynamics influencing its stock performance and strategic decisions. Key investors can exert considerable influence through their holdings and actions.

While specific real-time data on all investors and their direct impact is dynamic and may not be fully available, examining major institutional holders and significant individual investors provides insights. Institutional investors often hold substantial shares, and their trading activity can significantly affect stock prices. Recent moves, such as buying or selling large stakes, are closely watched by other investors as indicators of confidence or concern.

Here are some general considerations regarding investors in companies like Leap Therapeutics, Inc. (LPTX):

• Notable Investors: Identifying major institutional investors (e.g., Vanguard, BlackRock, State Street) and any activist investors who may have taken a stake in Leap Therapeutics, Inc. (LPTX).
• Investor Influence: Assessing how these investors, particularly those with large holdings, can influence company decisions through voting rights and engagement with management.
• Recent Moves: Monitoring recent SEC filings (e.g., 13D, 13G) to detect any significant changes in ownership, such as large stake acquisitions or disposals.

Institutional investors like Vanguard, BlackRock, and State Street often appear as major shareholders in many publicly traded companies. Their investment decisions are driven by various factors, including the company's financial health, growth prospects, and overall market conditions. Changes in their positions can reflect shifts in sentiment or strategic portfolio adjustments.

Activist investors may seek to influence company strategy or governance to unlock value. Their involvement can lead to significant changes in company direction, but also potential conflicts with existing management.

To gain a deeper understanding of Leap Therapeutics, Inc. (LPTX)'s financial standing, refer to this analysis: Breaking Down Leap Therapeutics, Inc. (LPTX) Financial Health: Key Insights for Investors

Leap Therapeutics, Inc. (LPTX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of Leap Therapeutics, Inc. (LPTX). This analysis encompasses the perspectives of major shareholders, recent market behaviors, and insights from analysts, providing a comprehensive view of the company's current standing.

Investor Sentiment:

Institutional ownership in Leap Therapeutics, Inc. (LPTX) is held by 84 institutional owners and shareholders, according to their filings with the Securities and Exchange Commission (SEC). These institutions collectively hold 20,725,972 shares. Major shareholders include:

• Gilead Sciences Inc.
• Samsara BioCapital, LLC
• Point72 Asset Management, L.P.
• 683 Capital Management, LLC
• Rock Springs Capital Management LP
• Vanguard Group Inc
• Baker Bros. Advisors Lp
• Simplify Asset Management Inc.
• PINK - Simplify Health Care ETF
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares

Recent hedge fund activity reveals mixed sentiment:

• 32 institutional investors increased their positions.
• 18 decreased their positions in the most recent quarter.

Key moves by hedge funds include:

• BALYASNY ASSET MANAGEMENT L.P. liquidated 3,085,104 shares (-100.0%) in Q4 2024, valued at approximately $8,869,674.
• POINT72 ASSET MANAGEMENT, L.P. acquired 1,400,000 shares (+inf%) in Q4 2024, with an estimated value of $4,025,000.
• CITADEL ADVISORS LLC reduced their holdings by 370,739 shares (-80.0%) in Q4 2024, worth around $1,065,874.
• MONACO ASSET MANAGEMENT SAM added 205,874 shares (+inf%) in Q4 2024, estimated at $591,887.
• BIT CAPITAL GMBH increased their stake by 201,008 shares (+248.2%) in Q4 2024, valued at $577,898.
• VANGUARD GROUP INC added 161,830 shares (+15.7%) in Q4 2024, estimated at $465,261.
• SUSQUEHANNA INTERNATIONAL GROUP, LLP increased their holdings by 159,842 shares (+241.3%) in Q4 2024, valued at $459,545.

The put/call ratio for Leap Therapeutics, Inc. (LPTX) is at 0.13, suggesting a generally bullish outlook.

Recent Market Reactions:

Leap Therapeutics Inc. (NASDAQ:LPTX) has experienced significant market volatility. As of April 16, 2025, the share price was $0.37, a substantial decrease from $3.00 on April 17, 2024, marking an 87.70% decline. The stock hit a 52-week low of $0.28 in early April 2025, reflecting an 89.12% decrease in stock value over the past year.

Despite these challenges, Leap Therapeutics, Inc. (LPTX) maintains a healthy current ratio of 3.41, indicating strong short-term liquidity.

Analyst Perspectives:

Analysts' opinions on Leap Therapeutics, Inc. (LPTX) have shifted recently. Several firms have downgraded their ratings:

• H.C. Wainwright downgraded the stock from Buy to Neutral.
• Baird revised its rating from Outperform to Neutral.

Baird also significantly reduced the price target to $1.25 from $9.00, citing ambiguous survival data and the company's financial outlook. Despite downgrades, the average analyst price target for Leap Therapeutics, Inc. (LPTX) is $3.00.

Rodman & Renshaw initiated coverage on June 28, 2024, with a Buy recommendation. The average one-year price target was $11.60 as of June 12, 2024, with forecasts ranging from $5.56 to $16.80.

Analysts at TradingView estimate Leap Therapeutics, Inc. (LPTX) price target at $6.75, with a maximum estimate of $8.00 and a minimum of $5.50.

These varied perspectives reflect the uncertainty surrounding Leap Therapeutics, Inc. (LPTX) future, influenced by clinical trial outcomes and strategic realignments.

For further insights into the company's financial standing, consider exploring: Breaking Down Leap Therapeutics, Inc. (LPTX) Financial Health: Key Insights for Investors.